928TiPATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma. (23rd October 2018) - Chowdhury, S; Feyerabend, S; Loriot, Y; Necchi, A; Gupta, S; Josephs, D H; Rodríguez-Vida, A; Srinivas, S; Zakharia, Y; Nepert, D; Wride, K; Thomas, D; et al.